"We are experiencing a temporary supply disruption with the Ozempic 1 mg pen due to the combination of overall global supply constraints coupled with increased demand," said Novo Nordisk spokesperson Kate Hanna in an emailed statement.
The 0.25 mg and 0.5 mg doses of Ozempic injection pens remain available "for patients with Type 2 diabetes across Canada," Hanna said. The lower-dose pens "may be an option for some patients to mitigate the impacts" of the supply disruption, Health Canada's web page said. Health Canada and Novo Nordisk are "closely monitoring" the supply of Rybelsus, which is the pill form of semaglutide, the active ingredient in Ozempic, the web page said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: